Together, these data suggest that inhibition of KAT6A enhances cell apoptosis in ovarian cancer cells and sensitivity of ovarian cancer cell to platinum-based chemotherapeutics by decreasing β-catenin. Here, KAT6A is linked to ovarian carcinoma.